Estonya - Estonca - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - bcg bakterid - intravesikaalsuspensiooni pulber ja lahusti - 1tk

Estonya - Estonca - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 15mg 0.3ml 0.3ml 4tk; 15mg 0.3ml 0.3ml 2tk; 15mg 0.3ml 0.3ml 10tk; 15mg 0.3ml 0.3ml 6tk; 15mg 0.3ml 0.3ml 14tk; 15mg 0.3ml 0.3ml 12tk; 15mg 0.3ml 0.3ml 24tk; 15mg 0.3ml 0.3ml 15tk; 15mg 0.3ml 0.3ml 5tk; 15mg 0.3ml 0.3ml 11tk

Estonya - Estonca - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 7,5mg 0.15ml 0.15ml 6tk; 7,5mg 0.15ml 0.15ml 24tk; 7,5mg 0.15ml 0.15ml 10tk; 7,5mg 0.15ml 0.15ml 11tk; 7,5mg 0.15ml 0.15ml 2tk; 7,5mg 0.15ml 0.15ml 5tk; 7,5mg 0.15ml 0.15ml 12tk; 7,5mg 0.15ml 0.15ml 14tk; 7,5mg 0.15ml 0.15ml 4tk; 7,5mg 0.15ml 0.15ml 1tk

Estonya - Estonca - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 22,5mg 0.45ml 0.45ml 14tk; 22,5mg 0.45ml 0.45ml 1tk; 22,5mg 0.45ml 0.45ml 10tk; 22,5mg 0.45ml 0.45ml 2tk; 22,5mg 0.45ml 0.45ml 11tk; 22,5mg 0.45ml 0.45ml 12tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - arseentrioksiid - leukeemia, promüelotsüütne, äge - antineoplastilised ained - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. vastuse määr muude ägeda müeloidse leukeemia alatüüpi, et arseentrioksiid ei ole uuritud.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

pfizer europe ma eeig  - rimegepant - migreenihäired - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.